Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm

G. Valero-López a,b,*, E. Carreón-Guarnizo a,b,c, R. Hernández-Clares a,b,c, F. Iniesta-Martínez e, J. Jiménez-Vega a,b,c, A. Moreno-Docon d, M.A. Iborra-Bendicho d, A. Morales-Ortiz a, J.E. Meca-Lallana a,b,c

a Servicio de Neurología, Hospital Clínico Universitario "Virgen de la Arrixaca", IMIB-Arrixaca, Murcia, Spain
b CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario "Virgen de la Arrixaca", IMIB-Arrixaca, Murcia, Spain
c Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain
d Servicio de Microbiología, Unidad de Virología, Hospital Clínico Universitario "Virgen de la Arrixaca", IMIB-Arrixaca, Murcia, Spain

Received 14 May 2020; accepted 1 June 2020

KEYWORDS
SARS-COV-2; Multiple sclerosis; COVID-19; Immunosuppressants; PCR

Abstract
Introduction: The COVID-19 pandemic is changing approaches to diagnosis, treatment, and care provision in multiple sclerosis (MS). During both the initial and peak phases of the epidemic, the administration of disease-modifying drugs, typically immunosuppressants administered in pulses, was suspended due to the uncertainty about their impact on SARS-CoV-2 infection, mainly in contagious asymptomatic/presymptomatic patients. The purpose of this study is to present a safety algorithm enabling patients to resume pulse immunosuppressive therapy (PIT) during the easing of lockdown measures.

Methods: We developed a safety algorithm based on our clinical experience with MS and the available published evidence; the algorithm assists in the detection of contagious asymptomatic/presymptomatic cases and of patients with mild symptoms of SARS-CoV-2 infection with a view to withdrawing PIT in these patients and preventing new infections at day hospitals.

Results: We developed a clinical/microbiological screening algorithm consisting of a symptom checklist, applied during a teleconsultation 48 h before the scheduled session of PIT, and PCR testing for SARS-CoV-2 in nasopharyngeal exudate 24 h before the procedure.

* Please cite this article as: Valero-López G, Carreón-Guarnizo E, Hernández-Clares R, Iniesta-Martínez F, Jiménez-Vega J, Moreno-Docon A, et al. Tratamiento inmunosupresor en pulsos en esclerosis múltiple durante el desescalado de la epidemia por SARS-CoV-2. Algoritmo de seguridad. Neurología. 2020. https://doi.org/10.1016/j.nrl.2020.06.001
* Corresponding author.
E-mail address: gabivalopez@gmail.com (G. Valero-López).

2173-5808/© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusion: The application of our safety algorithm presents a favourable risk-benefit ratio despite the fact that the actual proportion of asymptomatic and presymptomatic individuals is unknown. Systematic PCR testing, which provides the highest sensitivity for detecting presymptomatic cases, combined with early detection of symptoms of SARS-CoV-2 infection may reduce infections and improve detection of high-risk patients before they receive PIT.

© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

The COVID-19 pandemic that began in early 2020 represents a challenge for healthcare systems worldwide. All healthcare levels have been affected, from emergency and intensive care departments to hospital and outpatient healthcare services. This situation has led to an urgent reorganisation of medical care and a change in the direct relationship with the patient.

Multiple sclerosis (MS) units have been no exception, and telemedicine has become a very useful strategy to reduce in-person consultations and limit the risk of infection. However, many interventions performed at MS units require the physical attendance of patients; these include the parenteral (and oral) administration of pulse immunosuppressive therapy (PIT), especially at day hospitals (Table 1). Using immunosuppressants while maintaining adequate safety measures represents a true challenge and a test of the Spanish healthcare system’s capacity for adaptation.

Given the current lack of scientific evidence, we must consider immunosuppressed patients as a high-risk population in the event of SARS-CoV-2 infection. However, prior experience with such other coronaviruses as SARS-CoV and MERS-CoV and the limited data available on SARS-CoV-2 infection in immunosuppressed patients do not currently suggest more severe symptoms in the event of infection. In any case, this situation poses a dilemma regarding the risk-benefit ratio of PIT.

Administration of PIT during the initial and peak stages of the pandemic was influenced by the lack of information on the prevalence of contagious, asymptomatic/presymptomatic carriers of the virus and the limited access to diagnostic tests. On the positive side, adherence to lockdown measures among MS patients in general (as in the general population), and immunosuppressed patients (considered a high-risk population) in particular, may have reduced the number of infections; this situation may change during the de-escalation phase.

During these stages, given the uncertainty about the consequences of SARS-CoV-2 infection in patients receiving PIT and the recommendations of several expert groups, the strategy used by many MS units has been to postpone the onset and administration of PIT, awaiting the end of the pandemic, in order to minimise the risk of infection of patients visiting hospital.

Considering that lockdown measures are now being eased, and that the available experience does not allow us to expect an end to
the pandemic in the short term, the strategy of delaying administration of PIT indefinitely is not acceptable due to the high risk of MS reactivation; therefore, a change of strategy is needed.

To do this, we developed an algorithm based on safety criteria, the main aim of which is to detect asymptomatic, presymptomatic, and mildly symptomatic patients with SARS-CoV-2 infection before scheduled PIT sessions.

**Objectives**

1. To avoid administering PIT to an unidentified infected patient/contagious asymptomatic patient (with active infection) or presymptomatic patient (in the incubation period).
2. To reduce the risk of infection of patients receiving PIT at day hospitals due to prolonged contact with an unidentified infected individual or contagious asymptomatic/presymptomatic individual.
3. To avoid these 2 situations in patients with mild symptoms suggestive of active SARS-CoV-2 infection.

**Material and methods**

The algorithm is based on our own clinical experience in the management and treatment of MS, the knowledge acquired during the COVID-19 pandemic, and a literature review of studies published on each topic during the pandemic.

We present an analysis of the rationale underpinning the inclusion of each objective and its fulfilment in the algorithm.

**Objective 1:** to avoid administering PIT to an unidentified infected patient/contagious asymptomatic patient (with active infection) or presymptomatic patient (in the incubation period).

- No clinical or experimental information or evidence is available on whether PIT may facilitate or exacerbate progression of SARS-CoV-2 infection or whether, to the contrary, it has no influence at all. For example, some studies with infected post-transplant immunosuppressed patients report that infection was not more severe than in the general population; however, the results are controversial. Several registries have been created to gather experience and increase understanding of this question.
- An empirical approach to the situation, based on the clinical experience with other diseases, would recommend avoiding administration of PIT to asymptomatic/presymptomatic infected patients.

**Objective 2:** to reduce the risk of infection in patients receiving PIT at a day hospital due to prolonged contact with an unidentified infected individual/contagious asymptomatic/presymptomatic individual.

- Although the prevalence of contagious, asymptomatic/presymptomatic carriers of the virus is unknown, cases of infection in the presymptomatic stage/incubation period have been reported. Experience from reported cases seems to indicate that, in mild cases, transmission of infection mainly occurs in the first week after symptom onset, from 1 to 2 days before to 5–6 days after. Patients with more severe symptoms are thought to be more contagious, and for a longer period.
- Restricting the number and duration of visits to healthcare facilities to decrease the risk of SARS-CoV-2 infection is not applicable to patients requiring PIT administration at day hospitals. However, patients may benefit from physical distancing measures and appointment scheduling.
- Considering that prolonged sessions are frequently necessary for PIT administration, the risk of susceptible individuals (other patients and healthcare staff) being infected by contagious asymptomatic/presymptomatic individuals should be reduced by avoiding their presence at day hospitals.

**Objective 3:** to avoid these 2 situations in patients with mild symptoms suggestive of active SARS-CoV-2 infection.

- Before the pandemic, the administration of PIT in patients with banal viral infections, even with mild symptoms (low-grade fever, headache) was already delayed in clinical practice. There is even greater justification for applying this reasoning to patients with mild symptoms, who should not attend a day hospital until infection with SARS-CoV-2 is ruled out.

**Results**

Our algorithm is structured around the application of a double screening: first a clinical and then a microbiological screening (Fig. 1).

**Clinical protocol**

Absence of symptoms compatible with SARS-CoV-2 infection is verified by telephone or e-mail, using a symptom checklist, for all patients scheduled to receive PIT. As nursing staff are responsible for administering PIT, and given their significant role in MS units, they are probably the best qualified professionals to conduct this check. The clinical protocol is applied 48h before and on the day of PIT session (Fig. 1).

**Symptom checklist:**

- Are you experiencing or have you experienced the following symptoms over the past 2 weeks?
  - Throat pain
  - Persistent cough
  - Diarrhoea
  - Anosmia

---

**Table 1** Drugs used in pulse immunosuppressive therapy for multiple sclerosis.

| Drug            | Indication   | Route of administration | Time (h) |
|-----------------|--------------|-------------------------|----------|
| Methylprednisolone | Relapse      | Parenteral              | 2.5      |
| Natalizumab     | RMS          | Parenteral              | 3        |
| Ocrelizumab     | RMS; PPMS    | Parenteral              | 5        |
| Alemtuzumab     | RMS          | Parenteral              | 8        |
| Cladribinea     | RMS          | Oral                    | –        |

PPMS: primary progressive multiple sclerosis; RMS: recurrent multiple sclerosis.

a Although cladribine is administered orally and does not require patients to attend a day hospital, it is included in the algorithm as it is a pulse-administered treatment.
Outcomes after the application of the clinical protocol:

- Symptomatic patient/suspected active infection: if infection is medically confirmed, PIT is postponed. Assessment by the infectious diseases unit
- Asymptomatic patient: application of the microbiological protocol

Microbiological protocol

- 1) The day before PIT (24 h before):
  - PCR test for SARS-CoV-2 in nasopharyngeal exudate
- 2) The day scheduled for the PIT session: verification of microbiology findings:
  - Negative result: patient may pass to the treatment room with protection measures (surgical mask and hand sanitiser)
  - Positive result: PIT is postponed. Assessment by the infectious diseases unit

Discussion

Our protocol proposes a double screening, with initial clinical telephone verification as triage for patients scheduled to receive PIT, with the aim of identifying mildly symptomatic patients. This enables us to channel patients to the systems established for clinical management of SARS-CoV-2 infection and to avoid appointments or treatments with potentially contagious patients.16

The exact sensitivity and specificity of PCR tests for SARS-CoV-2 in asymptomatic and presymptomatic individuals is unknown, but different studies seem to suggest that this is the test with the highest diagnostic yield in this stage (Table 2).19 One study suggests that jointly performing a PCR test and a SARS-CoV-2 IgM ELISA test significantly increases sensitivity (up to 98.6%) in very early stages in symptomatic and asymptomatic patients.20

In Spain, testing for SARS-CoV-2 infection frequently involves at least 2 types of diagnostic tests: PCR and rapid antibody tests.21

The latter is able to detect active infection of several days of progression, especially from the 7th day, so it would not be useful for detecting asymptomatic or presymptomatic cases. Availability of routine serology tests that discriminate between IgM and IgG antibodies would enable us more precisely to diagnose the stage of infection. The degree and duration of immunity after infection remain unknown.

The COVID-19 pandemic has given rise to unprecedented situations that represent a challenge for care provision at MS units. During the early and peak stages of the pandemic, delaying the onset and administration of scheduled PIT sessions was inevitable given the epidemiological context of high transmissibility, with an unknown percentage of contagious, asymptomatic/presymptomatic patients (which is currently subject to study) and limited availability of diagnostic tests. Clinical management of this situation was highly complex, as the administration of most of these treatments cannot be interrupted due to a high risk of MS reactivation with relapses and increased disability. In fact, with the aim of postponing doses or increasing intervals between sessions, non-validated biomarkers have been used in patients with MS.22

In these circumstances, the indefinite suspension of PIT administration is not a reasonable option, as the pandemic is not expected to end in the short term. Furthermore, once the peak of the pandemic seemed to have been overcome, measures were introduced to ease the lockdown of the general population. If this process does not meet the recommendations of the healthcare authorities, the risk of infection will be higher. In this context, the objective of our algorithm is to increase the safety of PIT administration, which would reduce the risk for asymptomatic or presymptomatic patients and the risk of infection for other immunosuppressed patients.

Table 2 Interpretation of diagnostic tests in all stages of SARS-CoV-2 infection.

| PCR | Ag | IgM | IgG | Interpretation |
|-----|----|-----|-----|----------------|
| +   | —  | —   | —   | Presymptomatic stage |
| +   | +/−| +/− | +/− | Initial stage (1–7 days) |
| +/−| —  | +   | +/− | 2nd stage (8–14 days) |
| +/−| —  | +/− | +/− | 3rd stage (>15 days) |
| —  | +/−| +   | +/− | Past infection |

Ag: viral antigen detection test; IgG: IgG antibody detection test; IgM: IgM antibody detection test; PCR: polymerase chain reaction.

Modified from: Carlos III Health Institute.19
Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm

There are currently no specific recommendations from clinical or official guidelines for this type of patients; therefore, we propose that this safety algorithm be applied in clinical practice.

Our proposal does present some limitations. The algorithm currently only includes PCR tests, whose results are only useful in the moment before PIT administration. Many PIs create a state of persistent immunosuppression during which patients are susceptible to infection; therefore, in order for this algorithm to be genuinely useful, it should be accompanied by patient education programmes to ensure adherence to protection measures (physical distancing, hygiene, use of face masks, etc) for the duration of the pandemic. Furthermore, we do not know the usefulness in clinical practice of testing populations at risk using this procedure.

Our algorithm may increase understanding of the prevalence and characteristics of SARS-CoV-2 infection in immunocompromised patients with MS. We aim to reassess its usefulness and make modifications based on the progression of the pandemic, and to report the results of its application.

Conclusion

This safety algorithm is intended to help ensure the continued use of the most adequate therapeutic options on an individual basis. Taking into account the risk-benefit ratio, the application of our algorithm would be beneficial despite the fact that the actual number of contagious, asymptomatic/presymptomatic patients is unknown. Systematic performance of PCR tests, which provide the highest sensitivity for detecting presymptomatic individuals, combined with an early detection system would reduce infections and facilitate the identification of high-risk patients before they receive PIT.

Funding

The authors have received no funding for this study.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Centro de coordinación de emergencias y enfermedades sanitarias. Información científico-técnica. Enfermedad por coronavirus COVID-19. Aportaciones: Inmunodepresión. Ministerio de Sanidad. Actualización 17 de abril de 2020. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/20200417JTCoronavirus.pdf.
2. Dantiga L. Coronaviruses y immunosupresos pacientes. The facts during the third epidemic. Liver Transpl. 2020. Mar 20. doi: 10.1002/lt.25756.
3. Giovannoni G., Hawkesa C, Lechner-Scottb J, Levyca M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2020.102073.
4. Costa-Frassard I, Moreno-Torres V, Meca-Lallana JM. Garcia-Domínguez Documento EMCAM (Esclerosis Múltiple Comunidad Autónoma de Madrid) para el manejo de pacientes con esclerosis múltiple durante la pandemia de SARS-CoV-2. Rev Neurol. 2020;70:329–40, http://dx.doi.org/10.33588/r.7009.2020155.
5. Brownlee W, Bourdett D, Bradley S, Killilea J, Ciccarelli O. Treating Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic. Neurology. 2020. Apr 2;10.1212/WNL.00000000009507.
6. Gueguen A, Roux P, Deschamps R, Mouginier A, Bensa C, Savatovsky J, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J NeurolNeurosurg Psychiatry. 2014;85(9):1038–40.
7. Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261:1170–7.
8. Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurol Ther. 2019;8(2):241–50.
9. Recomendaciones de tratamiento oncológico en pacientes con tumores testiculares en momentos de epidemia por COVID19. Presidente del Grupo Germinal, en nombre de los miembros de la Junta Directiva del Grupo Germinal. Valencia, 1 abril 2020.
10. Grupo de investigación español en cáncer de mama (GEICAM). Documento GEICAM sobre el manejo del paciente con cáncer de mama en la situación de pandemia de COVID-19 en España. 2 de abril de 2020. https://seom.org/images/GEICAM_Recomendaciones_COVID_19_Cancer_de_Mama.pdf.
11. Rothe C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. NEJM. 2020;382(10):970–1.
12. Song JY, et al. Covid-19 in South Korea - Challenges of Subclinical Manifestations. NEJM. 2020. Apr 6. doi: 10.1056/NEJMuc2001801.
13. Callaway E, Cyranoski D. China coronavirus: six questions scientists are asking. Nature. 2020;577:605–7.
14. Wölfel R, Cormann VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature. 2020. Apr 1. doi: 10.1038/s41586-020-2196-x.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9, http://dx.doi.org/10.1001/jama.2020.1585.
16. EMA. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic. Version 1 (20/03/2020).
17. Propuesta de medidas y cuestiones a considerar para la fase de transición de la pandemia por SARS-CoV-2 en España. a. Informe técnico de la Sociedad Española de Medicina Preventiva, Salud Pública e Higiene (SEMPSPH). Actualizado a 10 de abril de 2020. https://www.semppsph.org/images/Informe%20SEMPSPH.%20Propuesta%20de%20medidas%20y%20aspectos%20a%20considerar%20en%20la%20fase%20de%20la%20transici%C3%93n.pdf.
18. Bonavita S, Tedeschi G, Atreja A, Lavorgna L. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic. Neurol Sci. 2020;41(5):1007–9, doi: 10.1007/s10072-020-04391-9. Epub 2020 Apr 17.
19. Interpretación de las pruebas diagnósticas frente a SARS-CoV-2. Instituto de Salud Carlos III. Colaboración de la Sociedad Española de enfermedades infecciosas y microbiología clínica. Ministerio de Sanidad. Actualizado 22 de abril de 2020. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/INTERPRETACION_DE_LA_S_PRUEBAS.pdf.
20. Guo L, Ren L, Yang S, Xiao M, Chang Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020. Mar 21. pii: ciaa310. doi: 10.1093/cid/ciaa310.
21. Guía para la utilización de test rápidos de anticuerpos para COVID-19. Actualización 7 abril de 2020. Centro de Coordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Guia_test_diagnosticos_serologicos_20200407.pdf.

22. Kim SH, Kim W, Li XF, Jung IJ, Kim SHJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412–20.